You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

9 Results
Drug
Other Name(s): Votrient®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Drug
Other Name(s): Iclusig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Drug
Quick Link(s):
Patient Info Sheet
Jan 2018
Guidelines and Advice
Status: Current
ID: GL 8-11
Jan 2018
Guidelines and Advice
Status: Current
ID: PET 2017-2
Version: n/a
May 2018
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Statistical Reports
Apr 2018